B. Riley raised the firm’s price target on Capricor Therapeutics (CAPR) to $50 from $21 and keeps a Buy rating on the shares. The clinical data ...
Capricor jumps after Phase 3 data show Deramiocel improves heart function and slows muscle decline in Duchenne muscular ...
Capricor shows positive HOPE-3 results with endpoints met, regulatory uncertainty, and a strong cash runway into 2026. Find ...
In 105 boys and young men enrolled in the HOPE-3 trial, patients given deramiocel every three months for a year had 54% ...
The Company plans to submit its response to the CRL, including the results from the HOPE-3 trial, to address the Agency's previous requests for additional data.
Pivotal Phase 3 randomized, double-blind, placebo-controlled study (n=106) met the primary endpoint (PUL v2.0) and the key ...
Zacks Investment Research on MSN
CAPR stock skyrockets 282% in a week: Here's what you need to know
Shares of Capricor Therapeutics CAPR have skyrocketed 281.9% this week. The massive stock price surge was observed after the ...
Shares quadrupled now that the company appears on track to reverse an earlier FDA rejection of what could be the first ...
Capricor Therapeutics (CAPR) announced that the European Medicines Agency, EMA, has granted both Orphan Drug and Advanced Therapy Medicinal Product, ATMP, designations to its lead asset, deramiocel, ...
US rare diseases focused biotech Capricor Therapeutics shares closed up 371% at $29.96, having leapt a staggering 500% ...
Capricor Therapeutics, Inc. soars 450% on positive HOPE-3 DMD results. Discover market impact, growth potential, and risks.
Capricor Therapeutics has seen its modeled fair value estimate jump from about $20.60 to roughly $44.56 per share, as analysts grow more confident in Deramiocel's path from the clinic to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback